(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
04 November 2021 (04.11.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/220170 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61P 35/00* (2006.01)
C07D 519/00 (2006.01) *A61K 31/437* (2006.01)

(21) International Application Number:
PCT/IB2021/053486

(22) International Filing Date:
27 April 2021 (27.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/CN2020/087831
29 April 2020 (29.04.2020) CN

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, 4056 Basel (CH).

(72) Inventors: **FAIRHURST, Robin Alec**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **FRITSCH, Christine**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **GERSPACHER, Marc**; c/o Novartis Pharma AG, Lichstrasse, 4002 Basel (CH). **HINRICHS, Jürgen Hans-Hermann**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **LANGLOIS, Jean-Baptiste Georges Armand**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **LEBLANC, Catherine**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **LI, Tengfei**; c/o China Novartis Institutes for BioMedical Research Co., Ltd., 4218 Jinke Road, Pudong New Area, Shanghai 201203 (CN). **LORTHIOIS, Edwige Liliane Jeanne**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **MURA, Christophe**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **NIETO-OBERHUBER, Cristina Montserrat**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **TODOROV, Milen**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **VAUPEL, Andrea**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **WARIN, Nicolas**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **WILCKEN, Rainer**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*

(54) Title: COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-ALPHA AND THEIR METHODS OF USE

(57) **Abstract:** The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt form thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of disease. The compounds are inhibitors or modulators of HIF2alpha.



(I)

WO 2021/220170 A1